Acaster Lloyd Consulting poster presentations at ISPOR 2020

Earlier this week, Acaster Lloyd Consulting presented two posters at Virtual ISPOR 2020. These describe two preference studies in spinal muscular atrophy (SMA) led by Andrew Lloyd and Siu Hing Lo. One study examined patient and caregiver treatment preferences in SMA. The other study estimated disutilities for SMA using results from a general population discrete choice experiment. You can view copies of the posters here and here.

Andrew Lloyd presentation at the 4th EuroQol Academy meeting

This morning Andrew Lloyd is presenting a talk entitled ‘Measuring children’s health and HRQL with EQ-5D-Y: Values, scores and decisions’ at the 4th EuroQol Academy meeting in Prague. Please get in touch if you would like further information.

Scottish Medicines Consortium (SMC) have published assessment reports for two new treatments under their new process for treatment for rare disease

The SMC have recently approved Luxturna (a gene therapy for a rare type of inherited retinal dystrophy) and Crysvita (a treatment for X-linked hypophosphataemia which is a rare skeletal disorder). Both submissions highlight the challenges in understanding the impact of very rare conditions on patients’ health related quality of life (HRQL). Acaster Lloyd Consulting Ltd worked with both of these companies to capture data regarding the impact of the disease and treatment on HRQL; data which was used to inform cost effectiveness analyses. In their review of both treatments the SMC highlighted uncertainty regarding the HRQL data because the methods relied in part upon expert opinion. We are keen to highlight this in order to illustrate the challenges we face in capturing HRQL data in rare diseases. The treatments will be available for use in Scotland for 3 years while the companies collect more data on the impact of the treatments on patients and carers.

Decision making regarding the adoption of very high price, potentially very high value treatments is probably the most challenging area of Health Technology Assessment. Read more about the news from the SMC here.

Acaster Lloyd Consulting lead the team behind the first Cystic Fibrosis specific preference-based scoring algorithm

Our director Sarah Acaster led a study team to develop the first cystic fibrosis disease specific preference-based scoring algorithm based on the Cystic Fibrosis Quality of Life – Revised Questionnaire (CFQ-R). If you’re at the North American Cystic Fibrosis Conference (NACFC) this week you can be the first to see the results of this work in Poster Session 1, tomorrow at 11:15 – 1:45: ‘Development of the CFQ-R preference-based scoring algorithm’.

Read more here